Commentary on “Chronic pain, inflammatory biomarkers, and risks of mortality and cardiovascular disease in individuals with type 2 diabetes: a prospective cohort study” by Li et al

Dear Editor, Li et al report a prospective cohort study examining the relationships between chronic pain, systemic inflammation, and long-term risks of cardiovascular disease (CVD) and all-cause mortality in individuals with type 2 diabetes (T2D)[1]. The study addresses an underrecognized but prevalent condition, chronic pain, within a high-risk cardiometabolic population. Its novelty lies in framing chronic pain not merely as comorbidity but as a potential marker and mediator of cardiovascular risk through inflammatory pathways. Using a large, well-characterized cohort with prospective follow-up, the authors demonstrate that T2D patients with chronic pain, particularly those with elevated inflammatory biomarkers, have substantially higher risks of CVD events and premature mortality. The longitudinal design strengthens causal inference, while joint analyses of pain and inflammation reveal biologically plausible synergistic effects. These findings align with known links between chronic pain, systemic inflammation, and atherosclerotic progression. With the growing incorporation of AI-driven diagnostics into healthcare, robust oversight mechanisms are needed to ensure methodological clarity, ethical compliance, and dependable clinical performance. The TITAN Guidelines 2025 address these needs by providing clear recommendations for the standardized reporting and evaluation of AI applications in medicine[2]. Despite these strengths, several points require further discussion. First, although the analyses adjust for a range of demographic and clinical covariates, residual confounding remains a concern. Lifestyle factors, such as physical activity, diet quality, smoking intensity, and socioeconomic stressors, each closely linked to both chronic pain and cardiovascular risk, may not be fully captured[3]. Similarly, comorbid conditions common in T2D, including depression, osteoarthritis, and neuropathy, could partially mediate or confound the observed associations. Second, the reliance on self-reported measures to define chronic pain introduces potential misclassification and reporting bias. Self-report does not fully capture pain severity, duration, anatomical distribution, or underlying etiology, all of which may differentially relate to inflammatory burden and cardiovascular risk[4,5]. Incorporating objective or standardized pain assessments, such as validated pain scales, quantitative sensory testing, or clinician-adjudicated diagnoses, would enhance the precision and interpretability of future studies. Third, while inflammatory biomarkers serve as a useful proxy for systemic inflammation, the mechanistic pathways linking chronic pain to cardiovascular outcomes remain largely inferential[6]. The inclusion of more granular molecular data, e.g., cytokine profiles, markers of endothelial dysfunction, autonomic imbalance, or imaging-based assessments of subclinical atherosclerosis could strengthen causal inference and clarify whether inflammation acts primarily as a mediator, modifier, or parallel risk pathway[7]. Despite its limitations, the study has important clinical and public health implications. Chronic pain may serve as a simple, patient-centered marker of increased cardiovascular risk in individuals with T2D, highlighting the need to incorporate pain assessment into routine diabetes care. The findings also support integrated, multidisciplinary care models that address metabolic disease, pain, and inflammation together. Future research should focus on clarifying underlying mechanisms and determining whether pain or anti-inflammatory interventions can reduce cardiovascular events and mortality. Conclusion In conclusion, Li et al provide compelling evidence that chronic pain, particularly when accompanied by systemic inflammation, is a significant predictor of mortality and CVD in individuals with T2D. Their study broadens the clinical lens through which chronic pain is viewed, emphasizing its relevance not only to symptom management but also to long-term cardiovascular prognosis. This work makes a valuable contribution to the literature and supports a more holistic, multidisciplinary approach to diabetes care and risk stratification.